Targeting polo-like kinase 1 for cancer therapy

Nature Reviews Cancer

Volumn 6, Issue 4, 2006, Pages 321-330

  Strebhardt, Klaus ^a   Ullrich, Axel ^b,c  

^a GOETHE UNIVERSITY   (Germany)

^b AGENCY FOR SCIENCE   (Singapore)

^c MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ANTINEOPLASTIC AGENT; BI 2536; ENZYME INHIBITOR; HESPERADIN; MORIN; N [4 [6 METHOXY 7 (3 MORPHOLINOPROPOXY) 4 QUINAZOLINYLAMINO]PHENYL] BENZAMIDE; N [4 [6 METHOXY 7 (3 MORPHOLINOPROPOXY) 4 QUINAZOLINYLAMINO]PHENYL]BENZAMIDE; ON 01910; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHOTRANSFERASE INHIBITOR; POLO LIKE KINASE 1; QUERCETIN; SCYTONEMIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VX 680; WORTMANNIN;

AMINO ACID SUBSTITUTION; BREAST CANCER; CANCER; CANCER INHIBITION; CANCER THERAPY; CARCINOGENESIS; CELL CYCLE; CLINICAL TRIAL; COLORECTAL CANCER; DISEASE ASSOCIATION; DRUG POTENCY; DRUG TARGETING; ENDOMETRIUM CANCER; ENZYME STRUCTURE; ESOPHAGUS CARCINOMA; GENOMIC INSTABILITY; GLIOBLASTOMA; HEPATOBLASTOMA; HIGH THROUGHPUT SCREENING; HUMAN; IC 50; LUNG NON SMALL CELL CANCER; MELANOMA; MITOSIS; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; OROPHARYNX CARCINOMA; OVARY CANCER; PANCREAS CANCER; PAPILLARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; STOMACH CARCINOMA;

ANIMALS; CELL CYCLE; CELL CYCLE PROTEINS; FORECASTING; GENE SILENCING; HUMANS; MITOSIS; NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS;

EID: 33645316142     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1841     Document Type: Review

References (129)

1. Fenton, B. & Glover, D. M. A conserved mitotic kinase active at late anaphase-telophase in syncytial Drosophila embryos. Nature 363, 637-640 (1993).
2. Glover, D. M., Hagan, I. M. & Tavares, A. A. Polo-like kinases: a team that plays throughout mitosis. Genes Dev. 12, 3777-3787 (1998).
3. Clay, F. J., McEwen, S. J., Bertoncello, I., Wilks, A. F. & Dunn, A. R. Identification and cloning of a protein kinase-encoding mouse gene, Plk, related to the polo gene of Drosophila. Proc. Natl Acad. Sci. USA 90, 4882-4886 (1993).
4. Lake, R. J. & Jelinek, W. R. Cell cycle-and terminal differentiation-associated regulation of the mouse mRNA encoding a conserved mitotic protein kinase. Mol. Cell. Biol. 13, 7793-7801 (1993).
5. Holtrich, U. et al. Induction and down-regulation of PLK, a human serine/threonine kinase expressed in proliferating cells and tumors. Proc. Natl Acad. Sci. USA 91, 1736-1740 (1994).
6. Hamanaka, R. et al. Cloning and characterization of human and murine homologues of the Drosophila polo serine-threonine kinase. Cell Growth Differ. 5, 249-257 (1994).
7. Simmons, D. L., Neel, B. G., Stevens, R., Evett, G. & Erikson, R. L. Identification of an early-growth-response gene encoding a novel putative protein kinase. Mol. Cell. Biol. 12, 4164-4169 (1992).
8. Ouyang, B. et al. Human Prk is a conserved protein serine/threonine kinase involved in regulating M phase functions. J. Biol. Chem. 272, 28646-28651 (1997).
9. Holtrich, U. et al. Adhesion induced expression of the serine/threonine kinase Fnk in human macrophages. Oncogene 19, 4832-4839 (2000).
10. Fode, C., Motro, B., Yousefi, S., Heffernan, M. & Dennis, J. W. Sak, a murine protein-serine/threonine kinase that is related to the Drosophila polo kinase and involved in cell proliferation. Proc. Natl Acad. Sci. USA 91, 6388-6392 (1994).
11. Karn, T. et al. Human SAK related to the PLK/polo family of cell cycle kinases shows high mRNA expression in testis. Oncol. Reports 4, 505-510 (1997).
12. Mundt, K. E., Golsteyn, R. M., Lane, H. A. & Nigg, E. A. On the regulation and function of human polo-like kinase 1 (PLK1): effects of overexpression on cell cycle progression. Biochem. Biophys. Res. Commun. 239, 377-385 (1997).
13. Smith, M. R. et al. Malignant transformation of mammalian cells initiated by constitutive expression of the polo-like kinase. Biochem. Biophys. Res. Commun. 234, 397-405 (1997).
14. Eckerdt, F., Yuan, J. & Strebhardt, K. Polo-like kinases and oncogenesis. Oncogene 24, 267-276 (2005).
15. Stevenson, C. S. et al. Scytonemin-a marine natural product inhibitor of kinases key in hyperproliferative inflammatory diseases. Inflamm. Res. 51, 112-114 (2002).
16. Stevenson, C. S. et al. The identification and characterization of the marine natural product scytonemin as a novel antiproliferative pharmacophore. J. Pharmacol. Exp. Ther. 303, 858-866 (2002).
17. Liu, Y. et al. Wortmannin, a widely used phosphoinositide 3-kinase inhibitor, also potently inhibits mammalian polo-like kinase. Chem. Biol. 12, 99-107 (2005).
18. Steegmaier, M. et al. BI 2536, a potent and highly selective inhibitor of Polo-like kinase 1 (Plk1), induces mitotic arrest and apoptosis in a broad spectrum of tumor cell lines. Clin. Cancer Res. 11 (Suppl.), 9147 (2005).
19. Baum A et al. In vivo activity of BI 2536, a potent and selective inhibitor of the mitotic kinase Plk1, in a range of human cancer xenograft models. Clin. Cancer Res. 11 (Suppl.), 9146 (2005).
20. Mross K et al. A phase I single dose escalation study of the Polo-like kinase 1 (Plk1) inhibitor BI 2536 in patients with advanced solid tumors. Clin. Cancer Res. 11 (Suppl.), 9032 (2005).
21. Gumireddy, K. et al. ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell 7, 275-286 (2005).
22. Barr, F. A., Sillje, H. H. & Nigg, E. A. Polo-like kinases and the orchestration of cell division. Nature Rev. Mol. Cell Biol. 5, 429-440 (2004).
23. Xie, S., Xie, B., Lee, M. Y. & Dai, W. Regulation of cell cycle checkpoints by polo-like kinases. Oncogene 24, 277-286 (2005).
24. van Vugt, M. A. & Medema, R. H. Getting in and out of mitosis with Polo-like kinase-1. Oncogene 24, 2844-2859 (2005).
25. Golsteyn, R. M. et al. Cell cycle analysis and chromosomal localization of human Plk1, a putative homologue of the mitotic kinases Drosophila polo and Saccharomyces cerevisiae Cdc5. J. Cell Sci. 107, 1509-1517 (1994).
26. Golsteyn, R. M., Mundt, K. E., Fry, A. M. & Nigg, E. A. Cell cycle regulation of the activity and subcellular localization of Plk1, a human protein kinase implicated in mitotic spindle function. J. Cell Biol. 129, 1617-1628 (1995).
27. Lee, K. S., Yuan, Y. L., Kuriyama, R. & Erikson, R. L. Plk is an M-phase-specific protein kinase and interacts with a kinesin-like protein, CHO1/MKLP-1. Mol. Cell. Biol. 15, 7143-7151 (1995).
28. Sunkel, C. E. & Glover, D. M. polo, a mitotic mutant of Drosophila displaying abnormal spindle poles. J. Cell Sci. 89, 25-38 (1988).
29. Kitada, K., Johnson, A. L., Johnston, L. H. & Sugino, A. A multicopy suppressor gene of the Saccharomyces cerevisiae G1 cell cycle mutant gene dbf4 encodes a protein kinase and is identified as CDC5. Mol. Cell. Biol. 13, 4445-4457 (1993).
30. Ohkura, H., Hagan, I. M. & Glover, D. M. The conserved Schizosaccharomyces pombe kinase plo1, required to form a bipolar spindle, the actin ring, and septum, can drive septum formation in G1 and G2 cells. Genes Dev. 9, 1059-1073 (1995).
31. Arnaud, L., Pines, J. & Nigg, E. A. GFP tagging reveals human Polo-like kinase 1 at the kinetochore/centromere region of mitotic chromosomes. Chromosoma 107, 424-429 (1998).
32. Wianny, F., Tavares, A., Evans, M. J., Glover, D. M. & Zernicka-Goetz, M. Mouse polo-like kinase 1 associates with the acentriolar spindle poles, meiotic chromosomes and spindle midzone during oocyte maturation. Chromosoma 107, 430-439 (1998).
33. Lee, K. S. & Erikson, R. L. Plk is a functional homolog of Saccharomyces cerevisiae Cdc5, and elevated Plk activity induces multiple septation structures. Mol. Cell. Biol. 17, 3408-3417 (1997).
34. Liu, X. & Erikson, R. L. Activation of Cdc2/cyclin B and inhibition of centrosome amplification in cells depleted of Plk1 by siRNA. Proc. Natl Acad. Sci. USA 99, 8672-8676 (2002).
35. Liu, X. & Erikson, R. L. Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc. Natl Acad. Sci. USA 100, 5789-5794 (2003).
36. Jang, Y. J., Lin, C. Y., Ma, S. & Erikson, R. L. Functional studies on the role of the C-terminal domain of mammalian polo-like kinase. Proc. Natl Acad. Sci. USA 99, 1984-1989 (2002).
37. Smits, V. A. et al. Polo-like kinase-1 is a target of the DNA damage checkpoint. Nature Cell Biol. 2, 672-676 (2000).
38. van Vugt, M. A., Bras, A. & Medema, R. H. Polo-like kinase-1 controls recovery from a G2 DNA damage-induced arrest in mammalian cells. Mol. Cell 15, 799-811 (2004).
39. van Vugt, M. A., Bras, A. & Medema, R. H. Restarting the cell cycle when the checkpoint comes to a halt. Cancer Res. 65, 7037-7040 (2005).
40. Ando, K. et al. Polo-like kinase 1 (Plk1) inhibits p53 function by physical interaction and phosphorylation. J. Biol. Chem. 279, 25549-25561 (2004).
41. Hanks, S. K., Quinn, A. M. & Hunter, T. The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science 241, 42-52 (1988).
42. Hanks, S. K. & Quinn, A. M. Protein kinase catalytic domain sequence database: identification of conserved features of primary structure and classification of family members. Methods Enzymol. 200, 38-62 (1991).
43. Guex, N. & Peitsch, M. C. SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 18, 2714-2723 (1997).
44. Bayliss, R., Sardon, T., Vernos, I. & Conti, E. Structural basis of Aurora-A activation by TPX2 at the mitotic spindle. Mol. Cell 12, 851-862 (2003).
45. Nowakowski, J. et al. Structures of the cancer-related Aurora-A, FAK, and EphA2 protein kinases from nanovolume crystallography. Structure. (Camb.) 10, 1659-1667 (2002).
46. Cheetham, G. M. et al. Crystal structure of aurora-2, an oncogenic serine/threonine kinase. J. Biol. Chem. 277, 42419-42422 (2002).
47. Yang, J. et al. Crystal structure of an activated Akt/& protein kinase B ternary complex with GSK3-peptide and AMP-PNP. Nature Struct. Biol. 9, 940-944 (2002).
48. Lowery, D. M., Lim, D. & Yaffe, M. B. Structure and function of Polo-like kinases. Oncogene 24, 248-259 (2005).
49. Hamanaka, R. et al. Polo-like kinase is a cell cycle-& regulated kinase activated during mitosis. J. Biol. Chem. 270, 21086-21091 (1995).
50. Marshall, C. J. Signal transduction. Hot lips and phosphorylation of protein kinases. Nature 367, 686 (1994).
51. Knighton, D. R. et al. Structure of a peptide inhibitor bound to the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science 253, 414-420 (1991).
52. Knighton, D. R. et al. Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science 253, 407-414 (1991).
53. Ellinger-Ziegelbauer, H. et al. Ste20-like kinase (SLK), a regulatory kinase for polo-like kinase (Plk) during the G2/M transition in somatic cells. Genes Cells 5, 491-498 (2000).
54. Walter, S. A., Cutler, R. E. Jr, Martinez, R., Gishizky, M. & Hill, R. J. Stk10, a new member of the polo-like kinase kinase family highly expressed in hematopoietic tissue. J. Biol. Chem. 278, 18221-18228 (2003).
55. Kelm, O., Wind, M., Lehmann, W. D. & Nigg, E. A. Cell cycle-regulated phosphorylation of the Xenopus polo-& like kinase Plx1. J. Biol. Chem. 277, 25247-25256 (2002).
56. Elia, A. E. et al. The molecular basis for phosphodependent substrate targeting and regulation of Plks by the Polo-box domain. Cell 115, 83-95 (2003).
57. Cheng, K. Y., Lowe, E. D., Sinclair, J., Nigg, E. A. & Johnson, L. N. The crystal structure of the human polo-like kinase-1 polo box domain and its phospho-peptide complex. EMBO J. 22, 5757-5768 (2003).
58. Yaffe, M. B. & Cantley, L. C. Mapping specificity determinants for protein-protein association using protein fusions and random peptide libraries. Methods Enzymol. 328, 157-170 (2000).
59. Elia, A. E., Cantley, L. C. & Yaffe, M. B. Proteomic screen finds pSer/pThr-binding domain localizing Plk1 to mitotic substrates. Science 299, 1228-1231 (2003).
60. Lee, K. S., Grenfell, T. Z., Yarm, F. R. & Erikson, R. L. Mutation of the polo-box disrupts localization and mitotic functions of the mammalian polo kinase Plk. Proc. Natl Acad. Sci. USA 95, 9301-9306 (1998).
61. Pawson, T. & Nash, P. Assembly of cell regulatory systems through protein interaction domains. Science 300, 445-452 (2003).
62. Lin, C. Y. et al. Peripheral Golgi protein GRASP65 is a target of mitotic polo-like kinase (Plk) and Cdc2. Proc. Natl Acad. Sci. USA 97, 12589-12594 (2000).
63. Yarm, F. R. Plk phosphorylation regulates the microtubule-stabilizing protein TCTP. Mol. Cell. Biol. 22, 6209-6221 (2002).
64. Preisinger, C. et al. Plk1 docking to GRASP65 phosphorylated by Cdk1 suggests a mechanism for Golgi checkpoint signalling. EMBO J. 24, 753-765 (2005).
65. Lee, K. S., Song, S. & Erikson, R. L. The polo-box-dependent induction of ectopic septal structures by a mammalian polo kinase, plk, in Saccharomyces cerevisiae. Proc. Natl Acad. Sci. USA 96, 14360-14365 (1999).
66. Seong, Y. S. et al. A spindle checkpoint arrest and a cytokinesis failure by the dominant-negative polo-box domain of Plk1 in U-2 OS cells. J. Biol. Chem. 277, 32282-32293 (2002).
67. Yuan, J. et al. Polo-like kinase, a novel marker for cellular proliferation. Am. J. Pathol. 150, 1165-1172 (1997).
68. Wolf, G. et al. Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer. Oncogene 14, 543-549 (1997).
69. Knecht, R. et al. Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck. Cancer Res. 59, 2794-2797 (1999).
70. Knecht, R., Oberhauser, C. & Strebhardt, K. PLK (polo-like kinase), a new prognostic marker for oropharyngeal carcinomas. Int. J. Cancer 89, 535-536 (2000).
71. Strebhardt, K., Kneisel, L., Linhart, C., Bernd, A. & Kaufmann, R. Prognostic value of pololike kinase expression in melanomas. JAMA 283, 479-480 (2000).
72. Kneisel, L. et al. Expression of polo-like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease. J. Cutan. Pathol. 29, 354-358 (2002).
73. Takahashi, T. et al. Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers. Cancer Sci. 94, 148-152 (2003).
74. Macmillan, J. C., Hudson, J. W., Bull, S., Dennis, J. W. & Swallow, C. J. Comparative expression of the mitotic regulators SAK and PLK in colorectal cancer. Ann. Surg. Oncol. 8, 729-740 (2001).
75. Weichert, W. et al. Polo-like kinase 1 expression is a prognostic factor in human colon cancer. World J. Gastroenterol. 11, 5644-5650 (2005).
76. Yamada, S. et al. Expression profiling and differential screening between hepatoblastomas and the corresponding normal livers: identification of high expression of the PLK1 oncogene as a poor-prognostic indicator of hepatoblastomas. Oncogene 23, 5901-5911 (2004).
77. Ahr, A. et al. Identification of high risk breast-cancer patients by gene expression profiling. Lancet 359, 131-132 (2002).
78. Simizu, S. & Osada, H. Mutations in the Plk gene lead to instability of Plk protein in human tumour cell lines. Nature Cell Biol. 2, 852-854 (2000).
79. Llamazares, S. et al. polo encodes a protein kinase homolog required for mitosis in Drosophila. Genes Dev. 5, 2153-2165 (1991).
80. Sunkel, C. E. & Glover, D. M. polo, a mitotic mutant of Drosophila displaying abnormal spindle poles. J. Cell Sci. 89, 25-38 (1988).
81. Lane, H. A. & Nigg, E. A. Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes. J. Cell Biol. 135, 1701-1713 (1996).
82. Cogswell, J. P., Brown, C. E., Bisi, J. E. & Neill, S. D. Dominant-negative polo-like kinase 1 induces mitotic catastrophe independent of cdc25C function. Cell Growth Differ. 11, 615-623 (2000).
83. Liu, X., Lei, M. & Erikson, R. L. Normal cells, but not cancer cells, survive severe Plk1 depletion. Mol. Cell. Biol. 26, 2073-2108 (2006).
84. Spankuch-Schmitt, B. et al. Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells. Oncogene 21, 3162-3171 (2002).
85. Gray, P. J. Jr et al. Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer. Mol. Cancer Ther. 3, 641-646 (2004).
86. Spankuch-Schmitt, B., Bereiter-Hahn, J., Kaufmann, M. & Strebhardt, K. Effect of RNA silencing of polo-like kinase-1 (PLK 1) on apoptosis and spindle formation in human cancer cells. J. Natl Cancer Inst. 94, 1863-1877 (2002).
87. Reagan-Shaw, S. & Ahmad, N. Silencing of polo-like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: implications for the treatment of prostate cancer. FASEB J. 19, 611-613 (2005).
88. Nogawa, M. et al. Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer. J. Clin. Invest. 115, 978-985 (2005).
89. Spankuch, B. et al. Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1. J. Natl Cancer Inst. 96, 862-872 (2004).
90. Jackson, A. L. et al. Expression profiling reveals off-target gene regulation by RNAi. Nature Biotechnol. 21, 635-637 (2003).
91. Daub, H., Specht, K. & Ullrich, A. Strategies to overcome resistance to targeted protein kinase inhibitors. Nature Rev. Drug Discov. 3, 1001-1010 (2004).
92. Shawver, L. K., Slamon, D. & Ullrich, A. Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell 1, 117-123 (2002).
93. McInnes, C., Mezna, M. & Fischer, P. M. Progress in the discovery of polo-like kinase inhibitors. Curr. Top. Med. Chem. 5, 181-197 (2005).
94. Jessani, N. & Cravatt, B. F. The development and application of methods for activity-based protein profiling. Curr. Opin. Chem. Biol. 8, 54-59 (2004).
95. Walker, E. H. et al. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol. Cell 6, 909-919 (2000).
96. Ihle, N. T. et al. Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Mol. Cancer Ther. 3, 763-772 (2004).
97. Keen, N. & Taylor, S. Aurora-kinase inhibitors as anticancer agents. Nature Rev. Cancer 4, 927-936 (2004).
98. Wu, S. Y. et al. Discovery of a novel family of CDK inhibitors with the program LIDAEUS: structural basis for ligand-induced disordering of the activation loop. Structure. (Camb.) 11, 399-410 (2003).
99. Ditchfield, C. et al. Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J. Cell Biol. 161, 267-280 (2003).
100. Hauf, S. et al. The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint. J. Cell Biol. 161, 281-294 (2003).
101. Harrington, E. A. et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nature Med. 10, 262-267 (2004).
102. Sumara, I. et al. Roles of polo-like kinase 1 in the assembly of functional mitotic spindles. Curr. Biol. 14, 1712-1722 (2004).
103. Casenghi, M. et al. Polo-like kinase 1 regulates Nlp, a centrosome protein involved in microtubule nucleation. Dev. Cell 5, 113-125 (2003).
104. Murray, A. W. Recycling the cell cycle: cyclins revisited. Cell 116, 221-234 (2004).
105. Toyoshima-Morimoto, F., Taniguchi, E., Shinya, N., Iwamatsu, A. & Nishida, E. Polo-like kinase 1 phosphorylates cyclin B1 and targets it to the nucleus during prophase. Nature 410, 215-220 (2001).
106. Yuan, J. et al. Cooperative phosphorylation including the activity of polo-like kinase 1 regulates the subcellular localization of cyclin B1. Oncogene 21, 8282-8292 (2002).
107. Jackman, M., Lindon, C., Nigg, E. A. & Pines, J. Active cyclin B1-Cdk1 first appears on centrosomes in prophase. Nature Cell Biol. 5, 143-148 (2003).
108. Qian, Y. W., Erikson, E., Li, C. & Mailer, J. L. Activated polo-like kinase Plx1 is required at multiple points during mitosis in Xenopus laevis. Mol. Cell. Biol. 18, 4262-4271 (1998).
109. Toyoshima-Morimoto, F., Taniguchi, E. & Nishida, E. Plk1 promotes nuclear translocation of human Cdc25C during prophase. EMBO Rep. 3, 341-348 (2002).
110. Wasch, R. & Engelbert, D. Anaphase-promoting complex-dependent proteolysis of cell cycle regulators and genomic instability of cancer cells. Oncogene 24, 1-10 (2005).
111. Castro, A., Bernis, C., Vigneron, S., Labbe, J. C. & Lorca, T. The anaphase-promoting complex: a key factor in the regulation of cell cycle. Oncogene 24, 314-325 (2005).
112. Moshe, Y., Boulaire, J., Pagano, M. & Hershko, A. Role of Polo-like kinase in the degradation of early mitotic inhibitor 1, a regulator of the anaphase promoting complex/cyclosome. Proc. Natl Acad. Sci. USA 101, 7937-7942 (2004).
113. Hansen, D. V., Loktev, A. V., Ban, K. H. & Jackson, P. K. PlkI regulates activation of the anaphase promoting complex by phosphorylating and triggering SCFβTrCP-dependent destruction of the APC inhibitor Emi1. Mol. Biol. Cell 15, 5623-5634 (2004).
114. Ahonen, L. J. et al. Polo-like kinase 1 creates the tension-sensing 3F3/2 phosphoepitope and modulates the association of spindle-checkpoint proteins at kinetochores. Curr. Biol. 15, 1078-1089 (2005).
115. Liu, X., Zhou, T., Kuriyama, R. & Erikson, R. L. Molecular interactions of Polo-like-kinase 1 with the mitotic kinesin-like protein CHO1/MKLP-1. J. Cell Sci. 117, 3233-3246 (2004).
116. Neef, R. et al. Phosphorylation of mitotic kinesin-like protein 2 by polo-like kinase 1 is required for cytokinesis. J. Cell Biol. 162, 863-875 (2003).
117. Zhou, T., Aumais, J. P., Liu, X., Yu-Lee, L. Y. & Erikson, R. L. A role for Plk1 phosphorylation of NudC in cytokinesis. Dev. Cell 5, 127-138 (2003).
118. Yang, J. et al. Crystal structure of an activated Akt-protein kinase B ternary complex with GSK3-peptide and AMP-PNP. Nature Struct. Biol. 9, 940-944 (2002).
119. Tokumitsu, Y. et al. Prognostic significance of polo-like kinase expression in esophageal carcinoma. Int. J. Oncol. 15, 687-692 (1999).
120. Wolf, G. et al. Polo-like kinase: a novel marker of proliferation: correlation with estrogen-receptor expression in human breast cancer. Pathol. Res. Pract. 196, 753-759 (2000).
121. Weichert, W. et al. Polo-like kinase isoforms in breast cancer: expression patterns and prognostic implications. Virchows Arch. 446, 442-450 (2005).
122. Takai, N. et al. Expression of polo-like kinase in ovarian cancer is associated with histological grade and clinical stage. Cancer Lett. 164, 41-49 (2001).
123. Takai, N. et al. Polo-like kinase (PLK) expression in endometrial carcinoma. Cancer Lett. 169, 41-49 (2001).
124. Dietzmann, K., Kirches, E., von, B., Jachau, K. & Mawrin, C. Increased human polo-like kinase-1 expression in gliomas. J. Neurooncol. 53, 1-11 (2001).
125. Ito, Y. et al. Polo-like kinase 1 overexpression is an early event in the progression of papillary carcinoma. Br. J. Cancer 90, 414-418 (2004).
126. Weichert, W. et al. Overexpression of Polo-like kinase 1 is a common and early event in pancreatic cancer. Pancreatology. 5, 259-265 (2005).
127. Weichert, W. et al. Polo-like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades. Prostate 60, 240-245 (2004).
128. Mito, K. et al. Expression of Polo-like kinase (PLK1) in non-Hodgkin's lymphomas. Leuk. Lymphoma 46, 225-231 (2005).
129. Wipf, P. & Halter, R. J. Chemistry and biology of wortmannin. Org. Biomol. Chem. 3, 2053-2061 (2005).